Henry Xiong is an Oncology physician affiliated with Universal Technical Institute Dallas-Fort Worth. OpenAlex indexes 47 publications with 5,614 citations (h-index 19); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 W Magnolia Ave
Fort Worth, TX 761044611
Telephone
817-759-7000Provider last certified this registry record 6 Feb 2025.
Clinical trials
- Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
Sponsor: Taiho Pharmaceutical Co., Ltd.
- S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
Sponsor: SWOG Cancer Research Network
- CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- Exelixis Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
89.7%Other antiemetics82.3%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist7.1%Palonosetron hcl98%Ondansetron Odt2%Part D + Part B≥29 patients+ 3 more classes in this area
Sensory organs
7.8%Corticosteroid7.8%Dexamethasone sodium phosphate100%Part B, office-administered≥31 patientsNervous system
0.8%Opioid Agonist0.3%Morphine Sulfate Er57%Tramadol Hcl43%Part D<11 patientsGabapentinoids0.2%Gabapentin100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”